Peter Schwartz, MD

John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences; Vice Chair, Gynecology

Research Departments & Organizations

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure

Cancer Genetics

Yale Cancer Center: Genomics, Genetics, and Epigenetics

Office of Cooperative Research

Research Interests

Gynecology; Ovarian Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms

Research Summary

Ovarian cancer is currently the fifth most common cancer in American women and the fourth most common cause of female cancer deaths. A lack of early warning symptoms and a lack of tests highly sensitive for detecting the disease are the major cause for the high death rate. My research is involved with early detection of ovarian cancer by screening a population of women who have at least one first degree relative with ovarian cancer, thereby making them at higher risk than the population at large for the disease.

My research is also involved with identifying tumor markers which may be useful in early detection of ovarian cancer and in monitoring women who have themselves experienced ovarian cancer. We are interested in new and innovative ways of treating patients with ovarian cancer and are enroll women in a prospective trial of neoadjuvant chemotherapy. Finally, we see a large number of women at Yale with an aggressive form of uterine cancer, uterine papillary serous cancer. I have developed new clinical approaches that have been very successful in the treatment of women with early stages of this disease and am collaborating with colleagues in studying the molecular biology of this disease in order to develop new treatment strategies.

Specialized Terms: Ovarian Cancer; Uterine; Vaginal; Cervical and vulvar cancer; Screening for ovarian cancer

Extensive Research Description

Ovarian cancer is currently the fifth most common cancer in American women and the fourth most common cause of female cancer deaths. A lack of early warning symptoms and a lack of tests highly sensitive for detecting the disease are the major cause for the high death rate. My research is involved with early detection of ovarian cancer by screening a population of women who have at least one first degree relative with ovarian cancer, thereby making them at higher risk than the population at large for the disease.

My research is also involved with identifying tumor markers which may be useful in early detection of ovarian cancer and in monitoring women who have themselves experienced ovarian cancer. We are interested in new and innovative ways of treating patients with ovarian cancer and are enroll women in a prospective trial of neoadjuvant chemotherapy. Finally, we see a large number of women at Yale with an aggressive form of uterine cancer, uterine papillary serous cancer. I have developed new clinical approaches that have been very successful in the treatment of women with early stages of this disease and am collaborating with colleagues in studying the molecular biology of this disease in order to develop new treatment strategies.

Neoadjuvant chemotherapy in the treatment of patients with advanced ovarian cancer

Management strategies for women with uterine papillary serous cancer

Early detection of ovarian cancer

Treatment of the elderly with ovarian and/or uterine cancer

Clinical Trials

Conditions Study Title
Cervix A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Ovary Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer
Ovary ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Corpus Uteri A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Ovary A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Corpus Uteri A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated/ultramutated endometrial cancer identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP), A Pilot Study
Anus, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Cervix, Urinary Bladder NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Cervix Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Corpus Uteri, Other Female Genital A Phase II Evaluation of Afatinib

Edit this profile

Contact Info

Peter Schwartz, MD
Office Location
Farnam Memorial Building
310 Cedar Street, Ste Suite 328D

New Haven, CT 06510
Mailing Address
Obstetrics, Gynecology & Reproductive SciencesPO Box 208063
New Haven, CT 06520-8063